Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

被引:575
作者
Jones, Simon A. [2 ]
Scheller, Juergen [3 ]
Rose-John, Stefan [1 ]
机构
[1] Univ Kiel, Inst Biochem, D-24098 Kiel, Germany
[2] Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff, S Glam, Wales
[3] Univ Dusseldorf, Fac Med, Inst Biochem & Mol Biol 2, Dusseldorf, Germany
基金
英国惠康基金;
关键词
SOLUBLE IL-6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; INTERLEUKIN-6; RECEPTOR; ONCOSTATIN-M; TGF-BETA; ANTIINFLAMMATORY CYTOKINE; HEPATIC INFLAMMATION; EXPERIMENTAL-MODEL;
D O I
10.1172/JCI57158
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the beta-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
引用
收藏
页码:3375 / 3383
页数:9
相关论文
共 129 条
  • [1] Roles of STAT3 defined by tissue-specific gene targeting
    Akira, S
    [J]. ONCOGENE, 2000, 19 (21) : 2607 - 2611
  • [2] Interleukin 6 is required for the development of collagen-induced arthritis
    Alonzi, T
    Fattori, E
    Lazzaro, D
    Costa, P
    Probert, L
    Kollias, G
    De Benedetti, F
    Poli, V
    Ciliberto, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) : 461 - 468
  • [3] Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo
    Atreya, R
    Mudter, J
    Finotto, S
    Müllberg, J
    Jostock, T
    Wirtz, S
    Schütz, M
    Bartsch, B
    Holtmann, M
    Becker, C
    Strand, D
    Czaja, J
    Schlaak, JF
    Lehr, HA
    Autschbach, F
    Schürmann, G
    Nishimoto, N
    Yoshizaki, K
    Ito, H
    Kishimoto, T
    Galle, PR
    Rose-John, S
    Neurath, MF
    [J]. NATURE MEDICINE, 2000, 6 (05) : 583 - 588
  • [4] Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    Bachelot, T
    Ray-Coquard, I
    Menetrier-Caux, C
    Rastkha, M
    Duc, A
    Blay, JY
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (11) : 1721 - 1726
  • [5] Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model
    Barkhausen, Tanja
    Tschernig, Thomas
    Rosenstiel, Philip
    van Griensven, Martijn
    Vonberg, Ralf-Peter
    Dorsch, Martina
    Mueller-Heine, Annika
    Chalaris, Athena
    Scheller, Juergen
    Rose-John, Stefan
    Seegert, Dirk
    Krettek, Christian
    Waetzig, Georg H.
    [J]. CRITICAL CARE MEDICINE, 2011, 39 (06) : 1407 - 1413
  • [6] BAUMANN H, 1991, J BIOL CHEM, V266, P20424
  • [7] TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling
    Becker, C
    Fantini, MC
    Schramm, C
    Lehr, HA
    Wirtz, S
    Nikolaev, A
    Burg, J
    Strand, S
    Kiesslich, R
    Huber, S
    Ito, H
    Nishimoto, N
    Yoshizaki, K
    Nishimoto, N
    Galle, PR
    Blessing, M
    Rose-John, S
    Neurath, MF
    [J]. IMMUNITY, 2004, 21 (04) : 491 - 501
  • [8] gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis
    Bollrath, Julia
    Phesse, Toby J.
    von Burstin, Vivian A.
    Putoczki, Tracy
    Bennecke, Moritz
    Bateman, Trudie
    Nebelsiek, Tim
    Lundgren-May, Therese
    Canli, Oezge
    Schwitalla, Sarah
    Matthews, Vance
    Schmid, Roland M.
    Kirchner, Thomas
    Arkan, Melek C.
    Ernst, Matthias
    Greten, Florian R.
    [J]. CANCER CELL, 2009, 15 (02) : 91 - 102
  • [9] Cutting edge: Soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells
    Briso, Eva M.
    Dienz, Oliver
    Rincon, Mercedes
    [J]. JOURNAL OF IMMUNOLOGY, 2008, 180 (11) : 7102 - 7106
  • [10] Stat proteins and oncogenesis
    Bromberg, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) : 1139 - 1142